Sioufi A, Parisot C, Sandrenan N, Dubois J P
Biopharmaceutical Research Center, Laboratoires Ciba-Geigy, Rueil-Malmaison, France.
Methods Find Exp Clin Pharmacol. 1989 Mar;11(3):179-85.
Three analytical procedures were developed to determine nicotine in plasma, cotinine in plasma and, simultaneously, nicotine and cotinine in urine. After liquid or solid-phase extraction, the purified aqueous phase is injected into a high performance liquid chromatograph equipped with an ultra-violet detector using a CN Spheri-5 micron cartridge-column with an inner diameter of 4.6 mm and a length of 10 or 22 cm. The limit of quantitation for nicotine in plasma was around 8 to 15 ng/ml, that of cotinine in plasma around 50 ng/ml and that of nicotine and cotinine in urine around 170 ng/ml and 70 ng/ml, respectively. The limit of detection of nicotine in plasma was around 1 ng/ml and that of nicotine and cotinine in urine around 20 ng/ml and 10 ng/ml, respectively. The passive exposure to cigarette smoke by non-smokers and the "resting levels" of nicotine in plasma and urine of smokers were studied. The analytical methods were set up to study the pharmacokinetics and bioavailability of nicotine in healthy volunteers following single and repeated administrations of different doses of transdermal nicotine systems.
开发了三种分析方法来测定血浆中的尼古丁、血浆中的可替宁,以及同时测定尿液中的尼古丁和可替宁。经过液相或固相萃取后,将纯化的水相注入配备紫外检测器的高效液相色谱仪中,使用内径为4.6 mm、长度为10或22 cm的CN Spheri - 5微米柱。血浆中尼古丁的定量限约为8至15 ng/ml,血浆中可替宁的定量限约为50 ng/ml,尿液中尼古丁和可替宁的定量限分别约为170 ng/ml和70 ng/ml。血浆中尼古丁的检测限约为1 ng/ml,尿液中尼古丁和可替宁的检测限分别约为20 ng/ml和10 ng/ml。研究了非吸烟者被动接触香烟烟雾的情况以及吸烟者血浆和尿液中尼古丁的“静息水平”。建立了分析方法以研究健康志愿者在单次和重复给予不同剂量的经皮尼古丁系统后尼古丁的药代动力学和生物利用度。